Search results
HC Wainwright Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)
ETF DAILY NEWS· 8 hours agoBioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports ...
Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $120.40
ETF DAILY NEWS· 10 hours agoBioNTech SE (NASDAQ:BNTX – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat ...
BioNTech SE (NASDAQ:BNTX) Position Reduced by Vontobel Holding Ltd.
ETF DAILY NEWS· 1 day agoVontobel Holding Ltd. trimmed its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 33.7% during the fourth quarter, according to its most recent filing with the ...
BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume
ETF DAILY NEWS· 1 day agoBioNTech SE (NASDAQ:BNTX – Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 308,533 shares were traded during mid-day trading, a decline ...
AACR: BioNTech's Genentech-partnered cancer vax still providing immune response 3 years later
FierceBiotech· 2 weeks agoThree years after receiving BioNTech’s cancer vaccine in a phase 1 trial, patients with a...
BMO keeps Outperform on BioNTech shares amid promising vaccines development
Investing.com· 1 week agoOn Tuesday, BMO Capital Markets sustained its Outperform rating for BioNTech (NASDAQ: BNTX ) shares...
Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 21 hours agoPfizer stock is trading at a nine-year low as the drugmaker looks for its next big break after...
Who can get a Covid booster this spring and how can you book?
BBC via Yahoo News· 5 days agoSpring vaccinations will be available until 30 June. Which vaccine will people get? Vaccines from...
China's drugmakers can't sell mRNA shots but haven't quit yet
Reuters via Yahoo News· 7 hours agoChina's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 weeks agoThree-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor